Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix in Patients With Rheumatic Diseases
NCT04748939Phase 4Withdrawn
- Sponsor
- Tuen Mun Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Zoster vaccine recombinant in herpes zoster (HZ) (2 arms), sponsored by Tuen Mun Hospital. Primary endpoint: Humoral immune response to Shingrix at 12 weeks. Planned start Sep 2026; status: withdrawn.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT04748939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04748939.